Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6

(2013) Brandon S Pybus et al.   MALARIA JOURNAL

Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria

(2013) Jason W. Bennett et al.   NEW ENGLAND JOURNAL OF MEDICINE

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine

(2012) Brandon S Pybus et al.   MALARIA JOURNAL

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment

(2012) Christine M Walko et al.   PHARMACOGENOMICS

Optimising Strategies for Plasmodium falciparum Malaria Elimination in Cambodia: Primaquine, Mass Drug Administration and Artemisinin Resistance

(2012) Richard J. Maude et al.   PLoS One

The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites

(2012) Michael Delves et al.   PLOS MEDICINE

Primaquine in vivax malaria: an update and review on management issues

(2011) Deepika Fernando et al.   MALARIA JOURNAL

Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)

(2011) Geoffrey S Dow et al.   MALARIA JOURNAL

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

(2009) Shu-Feng Zhou   CLINICAL PHARMACOKINETICS

Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes

(2009) Shobana Ganesan et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific

(2008) N.J. Elmes et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE